▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 29, 2024

Market Now

Samsung BioLogics inks W34.6b CMO deal

  • PUBLISHED :September 12, 2018 - 09:47
  • UPDATED :September 12, 2018 - 09:47
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print
[DISCLOSURE] Samsung BioLogics (207940) announced on Sept. 12 that it has signed a CMO contract worth 34.56 billion won (US$30.68 million) with Immunomedics. 

This amounts to 7.4 percent of its 2017 revenue and the contract is valid until Dec. 31, 2025.

By Hwang You-mee (glamazon@heraldcorp.com)

EDITOR'S PICKS